A novel anti-CTLA-4 nanobody-IL12 fusion protein in combination with a dendritic cell/tumour fusion cell vaccine enhances the antitumour activity of CD8
Animals
Dendritic Cells
/ immunology
Single-Domain Antibodies
/ pharmacology
CD8-Positive T-Lymphocytes
/ immunology
Interleukin-12
/ immunology
CTLA-4 Antigen
/ immunology
Mice
Cancer Vaccines
/ immunology
Humans
Cell Line, Tumor
Recombinant Fusion Proteins
/ pharmacology
Neoplasms
/ therapy
Female
Antigens, Neoplasm
/ immunology
Cell Fusion
Adoptive therapy
CD8+ T cell
CTLA-4
IL-12
Nanobody
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
19 Oct 2024
19 Oct 2024
Historique:
received:
09
11
2023
accepted:
07
10
2024
medline:
20
10
2024
pubmed:
20
10
2024
entrez:
19
10
2024
Statut:
epublish
Résumé
We previously developed a nanobody targeting CTLA-4 and demonstrated that it can boost antitumour T-cell responses in vitro; however, the resulting responses after the injection of T cells into cancer models are usually weak and transient. Here, we explored whether fusing our nanobody to IL-12 would enable it to induce stronger, longer-lasting T-cell immune responses after exposure to immature dendritic cell and tumour cell fusions. The fusion protein enhanced the response of CD8 Our in vitro and in vivo results suggest the anticancer potential of our nanobody-interleukin fusion system and support the clinical application of this fusion approach for various nanobodies.
Sections du résumé
BACKGROUND
BACKGROUND
We previously developed a nanobody targeting CTLA-4 and demonstrated that it can boost antitumour T-cell responses in vitro; however, the resulting responses after the injection of T cells into cancer models are usually weak and transient. Here, we explored whether fusing our nanobody to IL-12 would enable it to induce stronger, longer-lasting T-cell immune responses after exposure to immature dendritic cell and tumour cell fusions.
RESULTS
RESULTS
The fusion protein enhanced the response of CD8
CONCLUSION
CONCLUSIONS
Our in vitro and in vivo results suggest the anticancer potential of our nanobody-interleukin fusion system and support the clinical application of this fusion approach for various nanobodies.
Identifiants
pubmed: 39427185
doi: 10.1186/s12951-024-02914-6
pii: 10.1186/s12951-024-02914-6
doi:
Substances chimiques
Single-Domain Antibodies
0
Interleukin-12
187348-17-0
CTLA-4 Antigen
0
Cancer Vaccines
0
Recombinant Fusion Proteins
0
Antigens, Neoplasm
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
645Subventions
Organisme : National Natural Scientific Foundation of China
ID : 82360559
Organisme : Guangxi Natural Science Foundation
ID : 2023GXNSFAA026298
Organisme : Guangxi Key R & D Plan
ID : AB18221084
Organisme : Guangxi Medical and Health Key Cultivation Discipline Construction Project, and Fund for the Development and Promotion of Suitable Medical and Health Technologies in Guangxi
ID : S2022107
Informations de copyright
© 2024. The Author(s).
Références
Xue Y, Che J, Ji X, et al. Recent advances in biomaterial-boosted adoptive cell therapy. Chem Soc Rev. 2022;51(5):1766–94.
doi: 10.1039/D1CS00786F
pubmed: 35170589
Hilligan KL, Ronchese F. Antigen presentation by dendritic cells and their instruction of CD4
doi: 10.1038/s41423-020-0465-0
pubmed: 32433540
pmcid: 7264306
Yin X, Chen S, Eisenbarth SC. Dendritic cell regulation of T Helper cells. Annu Rev Immunol. 2021;39:759–90.
doi: 10.1146/annurev-immunol-101819-025146
pubmed: 33710920
Hu Z, Chen J, Zhou S, et al. Mouse IP-10 gene delivered by Folate-modified Chitosan Nanoparticles and Dendritic/tumor cells Fusion Vaccine effectively inhibit the growth of Hepatocellular Carcinoma in mice. Theranostics. 2017;7(7):1942–52.
doi: 10.7150/thno.16236
pubmed: 28638480
pmcid: 5479281
Tang Z, Mo F, Liu A et al. A Nanobody Against cytotoxic T-Lymphocyte Associated Antigen-4 increases the Anti-tumor effects of specific CD8
Wang G, Mudgal P, Wang L, et al. TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma. Oncoimmunology. 2021;10(1):1955545.
doi: 10.1080/2162402X.2021.1955545
pubmed: 34377592
pmcid: 8331028
Vignali D, Kallikourdis M. Improving homing in T cell therapy. Cytokine Growth Factor Rev. 2017;36:107–16.
doi: 10.1016/j.cytogfr.2017.06.009
pubmed: 28690108
Egg D, Rump IC, Mitsuiki N, et al. Therapeutic options for CTLA-4 insufficiency. J Allergy Clin Immunol. 2022;149(2):736–46.
doi: 10.1016/j.jaci.2021.04.039
pubmed: 34111452
Penter L, Zhang Y, Savell A, et al. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021;137(23):3212–7.
doi: 10.1182/blood.2021010867
pubmed: 33720354
pmcid: 8351891
Hodi FS, O’Day SJ, McDermott. DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
doi: 10.1056/NEJMoa1003466
pubmed: 20525992
pmcid: 3549297
Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65.
doi: 10.1016/S1470-2045(20)30539-8
pubmed: 33285097
Kelley RK, Sangro B, Harris W et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for patients with Unresectable Hepatocellular Carcinoma: Randomized Expansion of a phase I/II Study.J clin Oncol,2021,39(27):2991–3001.
Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today 2016,21(7):1076–113.
Liu M, Li L, Jin D et al. Nanobody-A versatile tool for cancer diagnosis and therapeutics.Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2021,13(4):e1697.
Li D, Morisseau C, McReynolds CB, et al. Development of Improved double-nanobody sandwich ELISAs for human soluble Epoxide hydrolase detection in Peripheral Blood mononuclear cells of Diabetic patients and the Prefrontal cortex of multiple sclerosis patients. Anal Chem. 2020;92(10):7334–42.
doi: 10.1021/acs.analchem.0c01115
pubmed: 32253910
pmcid: 7744119
Wan R, Liu A, Hou X et al. Screening and antitumor effect of an antiCTLA-4 nanobody.Oncol Rep,2018,39(2):511–8.
Qian L, Tang Z, Yin S et al. Fusion of dendritic cells and Cancer-Associated fibroblasts for activation of Anti-tumor cytotoxic T Lymphocytes.J Biomed Nanotechnol,2018,14(10):1826–35.
Qasemi M, Behdani M, Shokrgozar MA, et al. Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell. Protein Expr Purif. 2016;123:19–25.
doi: 10.1016/j.pep.2016.03.004
pubmed: 26996993
Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011,22(6):868–76.
Glassman CR, Mathiharan YK, Jude KM, et al. Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell. 2021;184(4):983–99. e24.
Etxeberria I, Bolaños E, Quetglas JI et al. Intratumor adoptive transfer of IL-12 mRNA transiently Engineered Antitumor CD8
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.
doi: 10.1038/s41423-020-0488-6
pubmed: 32612154
pmcid: 7395159
Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27(1):74–95.
doi: 10.1038/cr.2016.157
pubmed: 28025976
Liu Y, Zheng P. Preserving the CTLA-4 checkpoint for Safer and more effective Cancer immunotherapy. Trends Pharmacol Sci. 2020;41(1):4–12.
doi: 10.1016/j.tips.2019.11.003
pubmed: 31836191
Zhang A, Ren Z, Tseng KF, et al. Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors. Sci Transl Med. 2021;13(605):eabg8693.
doi: 10.1126/scitranslmed.abg8693
pubmed: 34349035
pmcid: 10234635
Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother. 2002;51(6):299–310.
doi: 10.1007/s00262-002-0284-4
pubmed: 12111118
pmcid: 11034221